Objective: We investigated the influence of hormone therapy (HT) on submaximal central and peripheral function in healthy postmenopausal women after 12 weeks of endurance training.
xercise training is strongly recommended in postmenopausal women (PMW) to reduce coronary artery disease risk 1, 2 to counter the effects of osteoporosis 3, 4 and to improve body composition and overall health. 5 Endurance-trained women have a significantly lower risk for all-cause mortality and nonfatal cardiovascular events. 6 In addition, regular aerobic exercise is linked to enhanced vascular function, including decreased arterial stiffness 7<9 and improved endothelial function. 10 Increased arterial stiffness and endothelial dysfunction are independently and in combination linked with increased cardiovascular disease risk. 7<10 Similar to the benefits of exercise, estrogen administration in healthy PMW is also associated with improved endothelial function 11 and decreased arterial stiffness. 7 Despite early reports of estrogen administration reducing the risk of coronary heart disease, 12 recent randomized placebo-controlled trials reported either no benefit or an increased rate of cardiac events with hormone therapy (HT). 13, 14 Discordance between findings from observational studies and randomized control trials is suggested to be related to the type and timing of HT relative to the onset of menopause. 15, 16 In support of this Btiming hypothesis,[ 16 recent reanalysis of data from the Women's Health Initiative 14 has shown that younger and recently PMW (age range, 50-59 y) have lower absolute risks for adverse outcomes from HT initiation than do older and long-after PMW. 17 Randomized clinical trials are currently underway to specifically investigate the cardiovascular effects of HT and 17A-estradiol in recently PMW. 18, 19 Meanwhile, the administration of HT in women for the relief of menopausal and urogenital symptoms to avoid fractures and atrophy of connective tissue continues to be advocated. 20 In light of the recommendation for PMW to participate in regular aerobic exercise to elicit numerous health benefits, and the fact that approximately 28% of PMW aged 50 to 74 years are still prescribed HT in the United States alone, 21 potential cardiovascular interactions between these interventions are of clinical relevance. Knowledge of such interactions would help guide practitioners and patients toward appropriate HT and exercise decisions. However, the interaction between HT and cardiovascular hemodynamics in response to exercise training is not well understood in general, in particular, whether cardiovascular responses and adaptations to exercise training differ among users and nonusers of HT. Although improvements in peak and submaximal cardiovascular parameters, such as stroke volume (SV) and cardiac output, in response to short-term endurance training have previously been shown to be independent of HT status in health 22 and disease, 23 no controlled studies have been reported. As such, the purpose of this study was to examine the influence of HT on central and peripheral function before and after 12 weeks of aerobic exercise training using a randomized, placebo control design in healthy PMW. Considering the well-known benefits of estrogen on vascular function, 7, 11, 24 it was hypothesized that HT would confer greater improvements to central and peripheral measures of cardiovascular function compared with nonusers.
METHODS

Study design
A randomized, double-blind, placebo-controlled, exercisetraining study was conducted. After medical screening, participants were randomly assigned to either HT or placebo control group (N-HT), with physiological assessmements made at baseline and after 12 weeks of aerobic training. The Human Research and Ethics Committee at the University of Toronto approved the study protocol, and written consent was obtained from all participants following the principles of the Declaration of Helsinki.
Study population
Participants included PMW who had undergone natural or surgical menopause and were amenorrheic for at least 1 year. Participants were recruited through gynecologist referrals and through local newspaper advertisements. The number of years since menopause was not recorded. A total of 37 PMW were recruited during a 1-year period. A total of 14 (38%) participants either dropped out of the study or were excluded due to noncompliance to the exercise training for various reasons, including time commitment (n = 6), illness (n = 6), and orthopedic conditions that limited their ability to walk (n = 2). There were no dropouts associated with the HT. A total of 23 participants completed the study, 11 of which received HT and 12 received placebo (N-HT). Because we have previously demonstrated unaltered central cardiovascular function during submaximal aerobic exercise in response to 12 weeks of HT alone in healthy PMW, 24 we did not examine the independent effects of HT in the current study.
Eligibility criteria
Serum estradiol (E 2 ) and follicle-stimulating hormone levels confirmed postmenopause status (follicle-stimulating hormone 940 IU/L; E 2 G80 pmol/L). 24 Eligible participants were healthy and sedentary and had not performed regular exercise for at least 1 year. Exclusion criteria included diagnosed diabetes mellitus, use of any cardiac medications, or any orthopedic conditions likely to impede the ability to participate in exercise training and testing.
Randomization
Participants were randomized to either treatment or placebo groups and performed baseline measures before drug assignment, after which participants were given their package of pills for the study, consisting of either 1 mg oral 17Aestradiol or placebo. Micronized progesterone (200 mg), or placebo, was administered for those with and without an intact uterus, respectively, for a period of 10 days/month. This medication phase was positioned at approximately 3 weeks, after each E 2 treatment, for a total of 3 months. To minimize the effects of the progesterone, post-HT cardiovascular measures were obtained during the very last week of E 2 treatment. Participants were instructed to talk to the study physician, who was readily available, should they wish to discuss any symptoms or ask any questions regarding the HT treatment and not to share this information with the research team.
Anthropometry
Adiposity measures included body mass index and waist and hip circumference. The sum of skinfolds (in mm; John Bull, British Indicators) were obtained from three sites: suprailiac, triceps, and subscapular regions, with percent body fat estimations calculated using standard equations. 25 
Blood analysis
Blood samples, performed at the same time of day (8:00 AM-12:00 PM) during each visit to the laboratory, were drawn from the antecubital vein using standard venipuncture techniques. Serum E 2 , total testosterone, and progesterone were assessed in duplicate using competitive immunoassay methods (Ortho-Clinical Diagnostics Inc, Vitros Immunodiagnostic Products, Rochester, NY). Sex hormoneYbinding globulin (SHBG) was assessed using chemiluminescent immunometric assay methods (Immulite; Diagnostics Products Corporation, Los Angeles, CA). Serum was stored at j20-C, and all samples were run in the same assays to eliminate contributions from interassay variance. All intra-assay coefficients of variance were less than 8%. Assay sensitivities were 10 pmol/L for E 2 , 0.25 nmol/L for progesterone, less than 0.03 nmol/L for testosterone, and 0.02 nmol/L for SHBG. The free androgen index was calculated using the ratio of total testosterone to the concentration of SHBG. 26 
Graded exercise testing
Graded exercise to maximal effort was performed on an electrically braked cycle ergometer (Ergoline Ergometrics 800S) using standard open-spirometry techniques. The protocol included a 1-minute warm-up at zero load, with work rate increased by 15 watts/minute until exhaustion. An automated sphygmomanometer was used to record blood pressure each minute (Tango; Sun Tech Medical Instruments). Measures of peak oxygen uptake (VO 2 peak), minute ventilation, ventilatory threshold (VT), peak work rate, and peak HR were obtained as described previously by our group. 24 The VT was determined using the break point in the ventilatory equivalent. 27 Menopause, Vol. 16 
Cardiac output and total peripheral resistance
A second exercise test was used to determine cardiac output (Q) during exercise using the equilibrium CO 2 rebreathing technique. 28 Three submaximal workloads of 30W, 45W, and 60W (corresponding to È40%, 50%, and 60% of peak work rate, respectively) were assessed. SV (in mL) was determined as Q divided by HR (in beats per minute). Total peripheral resistance (TPR) (in dynes s j1 cm j5 ) was calculated as (mean arterial pressure [MAP;
mm Hg]/Q [L/min]) Â 80.
Skeletal muscle blood flow
Resting calf blood flow (BF) and peak flow-mediated vasodilatory capacity were measured in the supine position using venous occlusion strain-gauge plethysmography (Vasculab SPG16; Medasonics, Mountain View, CA) as described previously. 24, 29 Briefly, an indium-gallium strain gauge was used with an occlusion cuff excluding BF to the foot. To produce maximal flow-mediated peripheral vasodilation, both cuffs were inflated to 200 mm Hg for 3 minutes, followed by ischemic plantar flexion exercise to fatigue on a specialized ergometer. BF was measured from the slope of the time-leg volume curve. Vascular conductance (G) was calculated as BF/MAP and is reported in mL I min j1 I 100 mL j1 I mmHg j1 . Test-retest reliability for BF measures in our laboratory yielded an intraclass correlation > of 0.91 for peak BF and 0.90 for resting BF. HR, MAP, and blood pressure were recorded from the middle finger on a beat-to-beat basis using the Finapres method (Finapres; Ohmeda, Englewood, CO).
Exercise training
Exercise training consisted of walking 5 days per week, with at least one supervised session per week. Each exercise session was composed of a 10-minute warm-up, a 45-minute aerobic conditioning (walking) session, and a 10-minute cooldown. For the first 2 weeks, participants were prescribed a walking intensity of 70% peak HR (È55% VO 2 peak), with training intensities increased to 75% to 80% peak HR (65%-75% VO 2 peak). 30 
Compliance
Treatment compliance was confirmed via pill counts at each testing time point and cross-referenced to serum hormone blood values. Exercise training compliance was confirmed by individual weekly training diaries, including completed distance (number of laps), total aerobic conditioning time, exercise HR, and subjective feelings. Failure to maintain 75% of the weekly prescription resulted in exclusion from the study sample.
Data analysis
The data were analyzed using the Statistical Package for the Social Sciences (SPSS Inc, Chicago, IL), version 11. The following calculation was used to determine the number of observations needed to provide an 80% probability of finding differences of 1.5 standard deviations in two-sample tests confirming the effects of HT and exercise at a significance level of 0.05 31 :
Paired t tests were used for overall effects, and independent t tests were used for the differences between groups (HT and N-HT) at baseline. Effects of exercise were calculated as postexercise training measures versus baseline measures. Independent t tests were used to detect differences in effects of exercise training between groups (HT and N-HT). The Bonferroni correction was applied for multiple comparisons. All data are reported as means T SEM and are considered statistically significant at P G 0.05.
RESULTS
Participant characteristics
Baseline participant characteristics are presented in Table 1 . Groups were similar (P 9 0.05) in age, height, weight, percent body fat, lean body mass, total fat mass, and body mass index. Significant reductions (P G 0.05) in waist circumference, percent body fat, and total fat mass were observed within, but not between, groups after exercise training. Body mass was not altered (P 9 0.05) after 12 weeks of exercise training.
Serum hormones
There were no significant differences in serum hormone measures between the groups at baseline (see Table 2 ). As expected, serum E 2 concentration increased significantly (P G 0.05) from 43.6 T 3.5 to 581.4 T 65.3 pmol/L after 3 months in the HT group but did not increase in the placebo group. Progesterone and testosterone levels did not increase 
Compliance
Pill counts confirmed compliance (100%) and were confirmed against hormone levels. The HT and placebo groups had a similar training HR at baseline (119 T 3 vs 114 T 2 beats/min), after 2 months (122 T 3 vs 116 T 2 beats/min), and after 3 months (123 T 2 vs 117 T 2 beats/min), as assessed during each training session. Total weekly distance walked was also similar between groups after 1, 2 and 3 months of training, respectively Training speed ranged between 4.6 and 4.8 km/hour for HT users and between 4.6 and 4.7 km/hour for nonusers (P 9 0.05). Frequency of training sessions did not differ between groups (P 9 0.05), with both groups attaining È85% to 95% of prescribed distances (P 9 0.05).
Submaximal cardiovascular responses
Data for Q, SV, HR, and TPR during 30W and 60W workloads are presented in Table 3 . There were no differences in physiological responses between groups, nor did HT influence any of the examined variables. In the sample as a whole, there was a significant training-induced lowering of HR at each of the three workloads (30W, P = 0.002; 45W, P = 0.002 [data not shown]; 60W, P = 0.001), along with a modest decrease in VO 2 at 30W (P = 0.014) and 60W (P = 0.040) in the group as a whole after training. There were no significant (P 9 0.05) changes in Q or calculated SV at any submaximal workload in either group. VO 2 peak and VT VO 2 peak and VT increased similarly between HT and N-HT groups (Fig. 1 ). Mean VO 2 peak at baseline HT, hormone therapy group; MAP, mean arterial pressure; N-HT, placebo control group; SV, stroke volume; TPR, total peripheral resistance; VO 2 , oxygen consumption. a P G 0.05 compared with baseline within groups. HT did not influence any cardiovascular measure. There were no differences between groups.
FIG. 1.
Oxygen uptake at ventilatory threshold (VT) (A) and peak oxygen uptake (VO 2 peak) (B) in the study groups before and after 3 months of aerobic training. *P G 0.05 from baseline within groups. No significant differences were detected between groups for VT and VO 2 peak before and after exercise training. HT, hormone therapy group; N-HT, placebo control group. (22.01 T 1.12 mL I kg j1 I min j1 ) increased by È9% after 12 weeks (24.34 T 1.36 mL I kg j1 I min j1 ) in the HT group. Similarly, N-HT women increased VO 2 peak È14% after 12 weeks from 21.06 T 1.72 to 23.45 T 1.48 mL I kg j1 I min j1 , matching the HT group's rate of increase. Similar changes were observed for the VT (in mL I kg j1 I min j1 ), which increased significantly (P G 0.05) within, but not between, groups. The HT group (13.10 T 0.46 mL I kg j1 I min j1 ) increased È9% after 12 weeks (14.96 T 0.97 mL I kg j1 I min j1 ), with corresponding VT values for the N-HT group being 11.90 T 1.31 to 12.17 T 1.09 mL I kg j1 I min j1 , representing an È5% increase. These increases were independent of HT status.
Peak HR, peak MAP, and VT HR were not significantly different (P 9 0.05) within or between groups at baseline or after 12 weeks of training. Peak and VT workload (in watts) were also similar (P 9 0.05) at baseline and after 12 weeks of training.
Peripheral vascular function
Resting and peak-ischemic BF responses were similar (P 9 0.05) at baseline. Increases in peak-ischemic BF failed to reach statistical significance after exercise training (P = 0.09) and was not influenced by HT (P = 0.43). Similarly, both groups demonstrated comparable (P 9 0.05) resting MAP and G at baseline, without any alteration after training. Baseline peak ischemic vascular resistance was also similar (P 9 0.05) between groups, with peak ischemic G increasing significantly (P G 0.05) within groups after training (0.39 T 0.03 to 0.46 T 0.03 mL I min j1 I 100 mL j1 I mmHg j1 in HT and 0.37 T 0.03 to 0.39 T 0.04 mL I min j1 I 100 mL j1 I mmHg j1 N-HT; Fig. 2 ). Using pooled data from both groups, improvements in peak ischemic G showed a significant effect of exercise (P = 0.032), but not for HT (P = 0.213).
DISCUSSION
In the current study, we demonstrate that 12 weeks of moderate aerobic exercise training is equally effective in conferring beneficial central and peripheral cardiovascular adaptations in users and nonusers of short-term HT in healthy PMW. After training, we observed decreased oxygen consumption and HR during each submaximal exercise workload, but SV, cardiac output, and TPR were unaltered in both groups. VO 2 peak and oxygen consumption at the VT were also increased in both groups. The gains in VO 2 peak occurred in the absence of central (cardiac) adaptation(s), although modest improvements in peripheral hemodynamics were observed. Collectively, our findings suggest that a short-term endurance exercise intervention in healthy PMW elicits similarly favorable cardiovascular health gains in users and nonusers of short-term HT.
Increased VO 2 peak in response to 3 months of aerobic training is consistent with the widely known physiological adaptations seen with regular endurance exercise. Despite the well-documented vasoregulatory effects of estrogen, HT did not confer a greater response. This is, in part, in contrast with evidence supporting an effect of HT on aerobic capacity in sedentary PMW. 32 It is possible, however, that the net effect of exercise training may be sufficient to overwhelm any subtle effects conferred by HT. Our observed exercise trainingYdependent increase in VO 2 peak (È9%) was similar to that reported by Lindheim et al 33 after 6 months of endurance training in PMW (age range, 42-59 y) with and without HT, training 3 days a week for 30 minutes at 70% HR peak. Others have also reported no effect of varying hormonal preparations and doses of HT on VO 2 peak after endurance training. 22,34<36 Similarly, studies demonstrate no effect of short-term HT alone on VO 2 peak in healthy PMW not undertaking exercise training. 24, 37, 38 Collectively, these data and ours support little or no effect of HT on VO 2 peak, irrespective of exercise training.
Our findings indicate that HT does not influence measures of SV, Q, TPR, or calculated arteriovenous oxygen difference during submaximal exercise in healthy PMW undergoing short-term endurance training. These findings are consistent with cross-sectional data reporting that long-term (92 y) HT fails to influence SV, Q, HR, TPR, and arteriovenous oxygen difference across a range (40%, 60%, and 80% VO 2 peak) of 36 Similarly, others demonstrate that long-term (91 y) HT is not associated with alterations in submaximal (60% of VO 2 peak) SV, Q, and arteriovenous oxygen difference after 20 weeks of aerobic training (55%-75% of VO 2 peak) in healthy young (age, È55 y) PMW. 22 These data and ours suggest that HT, both short-and long-term, does not alter central hemodynamic responses during submaximal exercise in aerobically trained and untrained PMW.
Given our failure to detect any influence of HT on central hemodynamic responses, we collapsed the data to compare the exercise trainingYdependent effects with other studies in PMW. Consistent with an effect of regular aerobic training, we observed a decrease in VO 2 and HR at each exercise intensity workload after 12 weeks of training. However, we did not observe changes in Q, SV, MAP, TPR, or arteriovenous difference. These changes are both consistent 39, 40 and inconsistent 22, 36 with previous studies. For example, Spina et al 40 reported no change in submaximal SV in conjunction with an increase in arteriovenous content difference in healthy older PMW (age [mean T SEM], 63 T 4 y) after 9 months of endurance training. Conversely, after 20 weeks of endurance training in younger (age, È55 y) PMW, Green et al 22 observed a significant increase in SV reported at 60% of VO 2 peak and at 50W. This group 22 also reported significant decreases in submaximal VO 2 , HR, and Q. In athletic, but not recreationally physically active PMW, McCole et al 36 reported exercise training-dependent gains in VO 2 , Q, and SV. Although the interaction between exercise training duration and exercise intensity on submaximal central adaptations is unclear, these studies suggest that improvements in central hemodynamic responses during exercise are greatly affected by exercise intensity, with higher intensity mediating greater improvements.
Despite evidence that HT has been shown to restore peripheral BF, 24, 41 vascular conductance, 24,41 endotheliumdependent vasodilation, 11 and TPR 42, 43 in estrogen-deficient PMW, we detected only modest nonsignificant gains in resting and peak ischemic calf BF and TPR. It is possible that our discordant findings may be due to the attenuation of estrogen-mediated vasodilation by progesterone. 44 Indeed, this could be an important factor in other studies reporting little or no effect of HT on submaximal hemodynamics. However, because we positioned testing at the farthest possible time point from the progesterone administration (3 wk), it is unlikely to have impacted our results.
The effects of aerobic exercise training on peripheral BF in PMW are unclear. We observed no significant effect of exercise training on BF. This is, in part, comparable with studies reporting no change in resting BF after 31 weeks of a walk/jog program at 70% to 90% of VO 2 peak for 45 minutes, 3 to 5 days per week in older (age [mean T SEM], 65 T 3 y) healthy PMW. 45 Conversely, peak ischemic blow flow has been shown to increase È18% 45 and È40% 46 in response to 32 weeks of endurance training. The greater increases in peak ischemic BF reported by Martin et al, 45 compared with that found in the current study, are likely due to the longer and more intense training program.
Limitations
Our sample size was small, and, as such, we may be underpowered to detect subtle differences between groups. Consequently, our findings should be interpreted with caution. The exclusion of an HT-only group in the present study also meant that we could not examine the independent effects of short-term HT alone on central and peripheral function. It is possible that our low-dose hormone regimen may not have been sufficient to confer improvement to central and peripheral function. Alternative hormonal preparations, doses, and/or duration of treatment may have impacted our parameters of interest differently. Of interest, recent studies have also indicated underlying vascular changes among women reporting hot flashes. 47 Because we did not document whether our PMW were experiencing vasomotor symptoms, we were not able to determine the effects of hot flashes on our cardiovascular measures. Finally, although frequency, distance walked, and exercise intensity were not reported to be different between the groups, absence of full supervision of the exercise training sessions may have also have affected our findings.
CONCLUSIONS
This study demonstrates that 12 weeks of aerobic training at a moderate intensity is equally effective in conferring increases to VO 2 peak and VO 2 at VT in users and nonusers of short-term HT in healthy PMW. This finding suggests that in the absence of disease, short-term HT does not influence peripheral or central cardiovascular adaptations. Further randomized controlled studies examining the long-term effects of HT and endurance training in women who have recently undergone menopause compared with those who are long-after the menopausal transition will help clarify the potentially independent and combined effects of these interventions in health and disease.
